The Why of GenAI
for Pharma

As GenAI evolves at a record pace, pharma commercial teams must keep pace without losing sight of the overall business strategy. Understanding, testing, and extracting value from GenAI is critical for the majority of commercial teams across the pharmaceutical, bio, and life sciences landscape today.

The potential impact of GenAI within pharma ranges from MLR, creative, audience building, targeting, patient support programs, field force content optimization, as well as the broader category of customer experience programs with both patients and physicians.

To Cut Through
the Clutter

With more literature about new treatments, devices, patient types… it’s no wonder that treaters remain overwhelmed with information. How can you Cut Through The Clutter?

In this project, The DHC Group and BGB Group surveyed over 100 Sermo network HCPs from a range of highly scientific and complex therapeutic areas including oncology, neurology, and immunology, on their current digital content consumption habits, preferences, and hopes for the future.

Social Media ROI

This report, featuring experts with varying perspectives, explores the range of thinking and calculating the ROI of a rapidly ascending and evolving channel.

To best capture industry perspective, The DHC Group conducted a DHCXN qualitative survey of decision makers from pharma/biotech/med device companies and did a series of quantitative DHCXN interviews, culminating in a panel discussion at the Uber Event’s Pharma CX Summit in October 2023.